馬賽替尼
Masitinib
Masitinib mesylate
別名: Masivet · Kinavet · Masitinib mesilate
由 VetSheet 獸醫團隊審訂更新於 2026年4月5日本內容以實證獸醫文獻為本
劑量為持牌獸醫專業人員的臨床參考。請務必對照最新藥品說明書及個別病患確認。
各物種劑量
🌎 NA — North America🌍 EU — Europe
狗
| 適應症 | 劑量 | 途徑 | 頻次 | 療程 | 地區 |
|---|---|---|---|---|---|
| Non-resectable mast cell tumours (Patnaik grade 2 or 3) | See Appendix for chemotherapy protocols | PO | unknown | unknown | 🌍 EU |
- Non-resectable mast cell tumours (Patnaik grade 2 or 3): Preferably with a confirmed mutated c-KIT tyrosine kinase receptor.
貓
| 適應症 | 劑量 | 途徑 | 頻次 | 療程 | 地區 |
|---|---|---|---|---|---|
| Injection site sarcoma, asthma (investigational) | Limited evidence: administered to healthy cats | PO | unknown | unknown | 🌍 EU |
- Injection site sarcoma, asthma (investigational): Not licensed in cats. Further clinical trials required. Monitor closely.
劑量為持牌獸醫專業人員的臨床參考。請務必對照最新藥品說明書及個別病患確認。
概覽
馬賽替尼是一種蛋白質酪氨酸激酶抑制劑，在獸醫學中主要用於治療犬隻無法切除的肥大細胞瘤，特別是確認帶有突變型 c-KIT 受體的病例。目前也正在研究其用於其他發炎和腫瘤疾病的潛力，如異位性皮膚炎、炎症性腸病、骨肉瘤和血管肉瘤。
臨床警告： 馬賽替尼是一種細胞毒性藥物。獸醫人員和寵物主人必須嚴格遵守安全和處理規程，以防止意外接觸。
作用機制
Masitinib acts as a protein tyrosine kinase (TK) inhibitor. It selectively and effectively binds with high affinity to mutated forms of the c-KIT tyrosine kinase receptor.
c-KIT receptor → Inhibition blocks the TK receptor pathways that are essential for cell replication, survival, and differentiation, thereby halting tumor growth and progression.
安全性與警告
禁忌症
- Pregnant or lactating bitches
- Dogs < 24 months old
- Dogs < 7 kg body weight
- Pre-existing signs of myelosuppression
- Previous hypersensitivity to masitinib
不良反應
- Diarrhoea (mild to moderate)
- Vomiting (mild to moderate)
- Hair coat changes or alopecia
- Renal toxicity
- Anaemia
- Protein loss (protein-losing nephropathy/enteropathy)
- Myelosuppression
- Increased liver enzyme activity
- Lethargy
- Cough
- Lymphadenomegaly
注意事項
Cytotoxic Handling: Handle with care using appropriate chemotherapeutic safety guidelines. Do not split or crush tablets.
Use with caution in patients with pre-existing renal or hepatic dysfunction.
Patients require intensive monitoring. Blood pressure, urinalysis, haematology, and biochemistry should be checked before starting therapy, and then at least once a month (or 1-2 weeks after initiation). Full coagulation profiles and faecal occult blood tests are required if adverse clinical signs occur.
藥物相互作用
May displace masitinib or be displaced, increasing the risk of adverse side effects
May alter the metabolism of masitinib, increasing the risk of toxicity or reducing efficacy
監測
- Blood pressure (baseline and monthly)
- Urinalysis (baseline and monthly)
- Haematology (baseline and monthly)
- Biochemistry (baseline and monthly)
- Coagulation profiles (if adverse signs witnessed)
- Faecal occult blood tests (if adverse signs witnessed)
- Weekly owner check-ins for the first 6 weeks to monitor for side effects
過量
No specific overdose information is provided in the monograph.
Clinical Pearl: Overdose of tyrosine kinase inhibitors typically exacerbates gastrointestinal toxicity (severe vomiting, diarrhea) and myelosuppression. Treatment is symptomatic and supportive. Monitor renal and hepatic parameters closely.
可用產品
劑型
- 150 mg film-coated tablet
獸醫用
- Masivet 50 mg film-coated tablets
- Masivet 150 mg film-coated tablets
各地核准狀態
POM-V. Licensed for dogs with non-resectable mast cell tumours.
POM-V. Licensed for dogs with non-resectable mast cell tumours.
暫無法規資料: 🇺🇸 US · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
儲存與穩定性
Store in accordance with cytotoxic drug guidelines. Keep out of reach of children and animals.
飼主須知
馬賽替尼是一種標靶癌症療法，主要用於治療犬隻的肥大細胞瘤。
- 處理注意事項： 這是一種危險藥物。在處理藥錠以及清理寵物排泄物（尿液、糞便、嘔吐物）時，請務必戴上拋棄式手套。處理後請徹底洗手。請勿剝半或壓碎藥錠。
- 監測： 您的寵物需要頻繁回診進行血液和尿液檢查，特別是在治療的前幾週，以確保藥物沒有影響其腎臟、肝臟或骨髓。
- 副作用： 密切觀察是否有嘔吐、腹瀉、嗜睡或毛髮改變的情況。如果您的寵物出現不適，請立即聯繫您的獸醫，因為需要及時處理副作用。
VetSheet 藥物參考供持牌獸醫專業人員作臨床決策輔助之用，不能取代專業判斷或廠方最新藥品說明書。